Loading…
UTI - Pharma & Healthcare Fund
Disclosed for 41 months, Jan 2014 to Jun 2017. This scheme is no longer reporting.
Portfolio value
₹279 Cr
up ₹15.6 Cr vs Jun 2015
- Stocks held
- 23
- unchanged
- Top 10 weight
- 75.3%
- of the portfolio in its ten largest
- Cash & debt
- 9.5%
- cash, money market and debt
UTI - Pharma & Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In July 2015 it disclosed 23 stocks worth ₹279 Cr, up ₹15.6 Cr from Jun 2015. Its largest positions were Sun Pharmaceutical Industries Limited (17.3%), Dr. Reddy's Laboratories Limited (14.1%), Lupin Limited (10.2%); the ten largest together made up 75.3% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 92.7% of its equity. Cash and debt stood at 9.5%. Compared with Jun 2015 the fund entered 0 new stocks and exited 0.
Against 230 other Sectoral / Thematic funds
Concentration
95%
Top-10 weight is higher than 95% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
93%
Holds more cash than 93% of peers
What these mean: concentration · cash
Holdings in July 2015
Download CSVEvery line the fund disclosed, with the change against Jun 2015. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 17.33% | down 2.19 pts | ₹48.3 Cr | down ₹3.1 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 14.10% | up 1.06 pts | ₹39.3 Cr | up ₹5 Cr | Added |
| Lupin Limited | 10.20% | down 2.87 pts | ₹28.4 Cr | down ₹6 Cr | Trimmed |
| Cipla Limited | 9.80% | up 0.79 pts | ₹27.3 Cr | up ₹3.6 Cr | Added |
| Cash, TREPS & receivables | 9.51% | up 3.61 pts | ₹26.5 Cr | up ₹11 Cr | Added |
| Aurobindo Pharma Limited | 5.75% | down 0.07 pts | ₹16 Cr | up ₹71 L | Added |
| Divi's Laboratories Limited | 5.73% | down 0.09 pts | ₹16 Cr | up ₹67 L | Added |
| Glenmark Pharmaceuticals Limited | 4.13% | down 0.17 pts | ₹11.5 Cr | up ₹20 L | Added |
| Zydus Lifesciences Limited | 2.96% | down 0.03 pts | ₹8.2 Cr | up ₹39 L | Added |
| Sun Pharma Advanced Research Company Limited | 2.82% | down 0.05 pts | ₹7.8 Cr | up ₹32 L | Added |
| Strides Pharma Science Limited | 2.45% | up 0.19 pts | ₹6.8 Cr | up ₹88 L | Added |
| IPCA Laboratories Limited | 2.31% | down 0.26 pts | ₹6.4 Cr | down ₹32 L | Trimmed |
| Pfizer Limited | 2.27% | up 0.04 pts | ₹6.3 Cr | up ₹46 L | Added |
| Biocon Limited | 1.90% | down 0.13 pts | ₹5.3 Cr | down ₹4 L | Trimmed |
| GlaxoSmithKline Pharmaceuticals Limited | 1.61% | down 0.01 pts | ₹4.5 Cr | up ₹22 L | Added |
| SHASUN PHARMACEUTICALS LTD. | 1.14% | up 0.13 pts | ₹3.2 Cr | up ₹52 L | Added |
| Natco Pharma Limited | 1.01% | down 0.05 pts | ₹2.8 Cr | up ₹4 L | Added |
| Sanofi India Limited | 0.98% | up 0.13 pts | ₹2.7 Cr | up ₹48 L | Added |
| Indoco Remedies Limited | 0.92% | down 0.11 pts | ₹2.6 Cr | down ₹15 L | Trimmed |
| Piramal Enterprises Limited | 0.90% | down 0.06 pts | ₹2.5 Cr | down ₹2 L | Trimmed |
| DISHMAN PHARMACEUTICALS & CHEMICALS LTD. | 0.75% | up 0.01 pts | ₹2.1 Cr | up ₹15 L | Added |
| Torrent Pharmaceuticals Limited | 0.74% | up 0.03 pts | ₹2.1 Cr | up ₹20 L | Added |
| Unichem Laboratories Limited | 0.46% | up 0.10 pts | ₹1.3 Cr | up ₹34 L | Added |
| Shilpa Medicare Limited | 0.24% | down 0.01 pts | ₹66 L | up ₹2 L | Added |
What changed, Jun 2015 to Jul 2015
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Dr. Reddy's Laboratories Limitedup ₹5 Cr (+1.06% pts)
- Cipla Limitedup ₹3.6 Cr (+0.79% pts)
- Strides Pharma Science Limitedup ₹88 L (+0.19% pts)
- Aurobindo Pharma Limitedup ₹71 L (−0.07% pts)
- Divi's Laboratories Limitedup ₹67 L (−0.09% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jun 2015, the weight rose most in Pharmaceuticals (+0.6 pts), and fell most in Pharmaceuticals & Biotechnology (−0.6 pts).
- Pharmaceuticals5.7% → 6.3%+0.6 pts
- Pharmaceuticals & Biotechnology93.2% → 92.7%−0.6 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2014 | Jan 2015 | Apr 2015 | Jun 2015 | Jul 2015 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 85.6% | 86.5% | 92.3% | 93.2% | 92.7% |
| Pharmaceuticals | 13.5% | 12.5% | 6.5% | 5.7% | 6.3% |
| Finance | 1.0% | 1.0% | 1.1% | 1.0% | 1.0% |
Allocation in Jul 2015change vs Jun 2015
- Pharmaceuticals & Biotechnology (17)92.7%▼ 0.6 pts
- Pharmaceuticals (5)6.3%▲ 0.6 pts
- Finance (1)1.0%
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Jul 2015
9.5%
▲ 3.6 pts vs Jun 2015
- Cash alone
- 9.5%
- cash and net receivables
- A year earlier
- 2.8%
- Jul 2014 · now ▲ 6.7 pts
- Last 12 months
- 2.1% – 9.5%
- lowest to highest · record 11.6% in Mar 2014
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.